Abstract
Background: Novel biomarkers which may serve as therapeutic targets are essential for lung cancer treatment. Here we investigated the prognostic significance of protein kinase Cη (PKCη, a cell cycle regulator involved in tumorigenesis and chemotherapy resistance, in patients diagnosed with non-small cell lung cancer (NSCLC). Patients and Methods: Sixty-three chemotherapy-naive patients were examined for PKCη by immunohistochemistry and divided into PKCη H-Score tertiles (low, intermediate and high). Time until event (relapse or mortality) within one year was determined using Cochran-Armitage test and Cox proportional hazards regression model. Results: The distribution of patients according to clinical stage 1-4 was: 27%, 5%, 26% and 42%, respectively. PKCη overexpression was associated with advanced stage (p=0.03) and the risk for an event (p=0.045). Patients of the lowest tertile were less likely to experience an event. Conclusion: PKCη is a novel prognostic marker in NSCLC that may predict poor prognosis. The use of PKCη-specific inhibitors in NSCLC may prove valuable.
Original language | English |
---|---|
Pages (from-to) | 1507-1513 |
Number of pages | 7 |
Journal | Anticancer Research |
Volume | 32 |
Issue number | 4 |
State | Published - 1 Apr 2012 |
Keywords
- Biomarker
- Non-small cell lung cancer
- PKCη
- Prognosis
- Protein kinase C
ASJC Scopus subject areas
- Oncology
- Cancer Research